This year's L. Michael Goldsmith Lecture will feature guest speaker Kim Yao, principal at Architecture Research Office. In advance of this annual New York City event, Yao shares a glimpse into her professional trajectory and the talk she has planned for September 25.
A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.
Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine.
A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.
Using an algorithm they call the Krakencoder, researchers at Weill Cornell Medicine are a step closer to unraveling how the brain’s wiring supports the way we think and act.
Hospices are increasingly owned by private equity firms and publicly traded companies, but recently Weill Cornell Medicine researchers found that they performed substantially worse than hospices owned by not-for-profit agencies.
Many people enrolled in Medicaid who require psychiatric care have difficulty accessing clinicians in a timely manner despite the higher need in this population, according to a study by researchers at Weill Cornell Medicine.
Ratan N. Tata ’59, B. Arch. ’62, one of India’s most influential and respected business leaders and philanthropists, and a former Cornell trustee who became the university’s largest international donor, died Oct. 9. He was 86.
Sakib Jamal ‘19 was recently chosen for the Forbes 30 Under 30 list, in part for his book, The Young VC's Handbook, a tactical guide for newcomers to venture capital.
A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.